Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
45°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Arrowhead Pharmaceuticals, Inc.
< Previous
1
2
3
4
Next >
Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock
January 03, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
December 29, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease
December 21, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 20, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results
November 29, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy
November 28, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals to Participate in Piper Sandler 35th Annual Healthcare Conference
November 21, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Year End Results
November 16, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals to Participate in Jefferies London Healthcare Conference
November 06, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals to Present New Phase 2 Clinical Data on Cardiometabolic Pipeline at AHA 2023
November 02, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming October 2023 Conferences
October 03, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
September 27, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Presents Data on Pulmonary Pipeline at ERS 2023
September 11, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming September 2023 Conferences
September 01, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results
August 07, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy
July 17, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 06, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1
June 27, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease
June 24, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming June 2023 Conferences
June 06, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Therapeutics
June 01, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
May 15, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results
May 02, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM™ Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect
April 25, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Second Quarter Results
April 18, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals to Host R&D Day on Pipeline of RNAi Therapeutics
April 12, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead
April 04, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
March 31, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Receives FDA Fast Track Designation for ARO-APOC3
March 20, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals to Present at 43rd Annual Cowen Health Care Conference
March 03, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.